Compare PPG Industries, Inc. (PPG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Summit Therapeutics Inc — how do they compare? PPG Industries, Inc. trades at $104.27 (market cap $23.44B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: PPG Industries, Inc. is the larger of the two by market cap, and PPG Industries, Inc. pays a 2.81% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Summit Therapeutics Inc for 16 Days on average.
| PPG | SMMT | |
|---|---|---|
Market Cap | $23.44B | $13.71B |
Volume | 2,064,777 | 6,173,057 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $26.38 |
52-Week Low | $94.34 | $12.43 |
Typical Hold Time | 68 Days | 16 Days |
Enterprise Value | $29.31B | $13.04B |
Dividend Yield | 2.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG Industries trades at $104.79, down 0.28% for the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported 2025 revenue of $15.88 billion and net income of $1.58 billion, with a P/E ratio of 15.13. Recent earnings showed mixed results, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Analyst consensus is a Buy with a $130 price target, while recent news highlights margin pressures in the Automotive Refinish segment.
The outlook for PPG is cautiously optimistic, supported by strong profitability metrics like a 9.57% net income margin and 19.63% ROE, but risks include segment-specific weaknesses and macroeconomic headwinds. Upside potential exists if the company meets Q3 2026 earnings expectations and sustains cost-control measures, though investors should monitor auto refinish performance and global demand trends.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
